Posted inNews and Updates
New Stem Cell Therapy Shows Promise for Parkinson’s Disease
A new clinical trial reveals that stem cell-derived dopamine cells are safe and effective for treating Parkinson’s disease symptoms. Learn more here.
Posted inNews and Updates
FDA Clears Investigational New Drug Application for FT839
Fate Therapeutics has received FDA clearance for its FT839 IND application. Learn how this iPSC-derived CAR-NK therapy is shaping the future of oncology.
Posted inNews and Updates
MAIA Biotechnology Reports Positive Phase II Trial Results
MAIA Biotechnology shares positive Phase II results for its novel NSCLC treatment, showing strong efficacy and potential for advanced lung cancer patients.
Posted inNews and Updates
Transforming MS Clinical Trials: A New Immune Focus
Discover how modern clinical trials are shifting focus toward immune-system dynamics to better treat multiple sclerosis and improve long-term patient care.
Posted inNews and Updates
Piramal Pharma Stock Climbs After US FDA Inspection Success
Piramal Pharma shares jumped 4% following a successful US FDA inspection. Learn how this regulatory milestone bolsters the company's global growth outlook.
Posted inNews and Updates
Real-World Evidence: Transforming Modern Clinical Trials
Discover how Real-World Evidence is reshaping clinical trials and accelerating drug development by using patient data from outside traditional study settings.
Posted inNews and Updates
AstraZeneca Shares Dip Following Clinical Trial Setback
AstraZeneca stock falls following a clinical trial failure. Get the latest analysis on the impact of this study and the firm’s future research outlook.
Posted inNews and Updates
AstraZeneca Stock Dips Following Heart Drug Trial Setback
AstraZeneca shares dropped 9% after a key heart drug trial failed. Read our analysis on the clinical impact and what this means for the company's future.
Posted inNews and Updates
SAT-3247 Shows Muscle Fat Reduction in DMD Patients
New trial data shows SAT-3247 reduces muscle fat infiltration in adults with Duchenne muscular dystrophy, offering a potential breakthrough in muscle repair.
Posted inNews and Updates
Setmelanotide Shows Promise for Hypothalamic Obesity
New phase 3 data shows setmelanotide effectively treats hypothalamic obesity by targeting MC4R signaling. Discover the potential breakthrough in weight loss.